

**Intervention on provisional agenda item 10. Substandard and falsified
medical products
156th WHO EXECUTIVE BOARD**

Honourable Chair, Distinguished Delegates,

Thank you for the opportunity to speak on behalf of the International Pharmaceutical Federation (FIP) the global organisation representing over four million pharmacists worldwide.

We welcome the WHO Member State mechanism's efforts to address substandard and falsified (SF) medical products and facilitate stakeholder collaboration.

FIP's collaboration with WHO highlights the crucial role of pharmacists in detecting and reporting SF products. Well-trained pharmacists, health care professionals with their direct patient access, in community and hospital settings can swiftly detect SF products in supply chains, report them to authorities, and educate and advise affected patients.

FIP's collaboration with WHO resulted in a competency framework and comprehensive course for pharmacy students that were implemented in African universities.¹ We are pleased to see WHO expanded the course for educational and regulatory institutions around the world.

Thank you for your attention.
(100 words)

¹ <https://www.fip.org/falsified-medicines>